Ask about this productRelated genes to: ZNF780A Blocking Peptide
- Gene:
- ZNF780A NIH gene
- Name:
- zinc finger protein 780A
- Previous symbol:
- -
- Synonyms:
- ZNF780
- Chromosome:
- 19q13.2
- Locus Type:
- gene with protein product
- Date approved:
- 2006-08-15
- Date modifiied:
- 2014-11-19
Related products to: ZNF780A Blocking Peptide
Related articles to: ZNF780A Blocking Peptide
- T-cell acute lymphoblastic leukemia (T-ALL) is a rare malignancy characterized by proliferation of early T-cell precursors that replace normal hematopoietic cells. T-ALL cells carry non-random chromosome aberrations, fusion genes, and gene mutations, often of prognostic significance. We herein report the genetic findings in cells from a T-ALL patient. - Source: PubMed
Panagopoulos IoannisAndersen KristinRinvoll Johannsdottir Inga MariaMicci FrancescaHeim Sverre - Myxofibrosarcoma (MFS) is a rare subtype of sarcoma, whose genetic basis is poorly understood. We analyzed 69 MFS cases using whole-genome (WGS), whole-exome (WES) and/or targeted-sequencing (TS). Newly sequenced genomic data were combined with additional deposited 116 MFS samples. WGS identified a high number of structural variations (SVs) per tumor most frequently affecting the TP53 and RB1 loci, 40% of tumors showed a BRCAness-associated mutation signature, and evidence of chromothripsis was found in all cases. Most frequently mutated/copy number altered genes affected known disease drivers such as TP53 (56.2%), CDKN2A/B (29.7%), RB1 (27.0%), ATRX (19.5%) and HDLBP (18.9%). Several previously unappreciated genetic aberrations including MUC17, FLG and ZNF780A were identified in more than 20% of patients. Longitudinal analysis of paired diagnosis and relapse time points revealed a 1.2-fold mutation number increase accompanied with substantial changes in clonal composition over time. Our study highlights the genetic complexity underlying sarcomagenesis of MFS. - Source: PubMed
Publication date: 2022/05/13
Takeuchi YasuhideYoshida KenichiHalik AdrianeKunitz AnnegretSuzuki HiromichiKakiuchi NobuyukiShiozawa YusukeYokoyama AkiraInoue YoshikageHirano TomonoriYoshizato TetsuichiAoki KosukeFujii YoichiNannya YasuhitoMakishima HidekiPfitzner Berit MariaBullinger LarsHirata MasahiroJinnouchi KeitaShiraishi YuichiChiba KenichiTanaka HirokoMiyano SatoruOkamoto TakeshiHaga HironoriOgawa SeishiDamm Frederik - Hepatocellular carcinoma (HCC) is one of the most devastating diseases worldwide. Limited performance of clinicopathologic parameters as prognostic factors underscores more accurate and effective biomarkers for high-confidence prognosis that guide decision-making for optimal treatment of HCC. The aim of the present study was to establish a novel panel to improve prognosis prediction of HCC patients, with a particular interest in transcription factors (TFs). - Source: PubMed
Publication date: 2020/12/01
Zhou Tian-HaoSu Jing-ZhiQin RuiChen XiJu Gao-DaMiao Sen - Infants born very preterm are more likely to experience neonatal morbidities compared to their term peers. Variations in DNA methylation (DNAm) associated with these morbidities may yield novel information about the processes impacted by these morbidities. - Source: PubMed
Publication date: 2020/10/19
Everson Todd MO'Shea T MichaelBurt AmberHermetz KarenCarter Brian SHelderman JenniferHofheimer Julie AMcGowan Elisabeth CNeal Charles RPastyrnak Steven LSmith Lynne MSoliman AntoineDellaGrotta Sheri ADansereau Lynne MPadbury James FLester Barry MMarsit Carmen J